帕佐帕尼布在软组织肉瘤中的现实环境:来自意大利国家注册表的数据
B Vincenzi1, P P Olimpieri2, S Celant2
1Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy; Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
ESMO open
|November 28, 2024
概括
在晚期软组织肉瘤 (STS) 中,pazopanib治疗的持续时间因患者因素和组织学而异. 这项意大利实践研究的结果反映了关键试验结果,突出了罕见亚型的潜在差异.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 帕佐帕尼布 (Pazopanib) 是一种治疗先进的非脂肪细胞软组织肉瘤 (STS) 的药物,该药物是在先前的化疗后使用的.
- 在不同的STS组织学中使用帕佐帕尼布的最佳使用需要进一步定义.
研究的目的:
- 评估意大利高级STS患者中pazopanib的实际有效性和治疗模式.
- 确定影响治疗终止时间 (TTD) 和剂量减少的因素.
主要方法:
- 在2013年7月至2019年12月期间,全国范围内对先进的STS患者进行了一项观察性队列研究,这些患者接受了pazopanib治疗.
- 通过意大利药物管理局 (AIFA) 药物监测注册表前性收集的数据.
- 主要结局:治疗终止的时间 (TTD);次要结局:剂量减少的频率和时间.
主要成果:
- 分析了1964年STS患者的数据;最常见的亚型是乳腺髓肉瘤 (44.7%) 和不分化的肉瘤 (11.5%).
- 中位数的TTD为106天. 较短的TTD与较差的性能状态,更多的先前治疗和较低的帕佐帕尼布剂量有关.
- 恶性单一纤维性瘤与不分化瘤相比,显示了较长的TTD.
结论:
- 在先进的STS中,pazopanib的实际结果与关键的PALETTE试验相当.
- 该研究包括多种不同的STS亚型,包括罕见的亚型,这表明在组织学之间治疗持续时间的潜在差异.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...